Reirradiation for Locoregional Recurrent Breast Cancer

医学 不良事件通用术语标准 四分位间距 不利影响 乳腺癌 放射治疗 核医学 癌症 内科学
作者
Sayeh Fattahi,Safia K. Ahmed,Sean S. Park,Ivy A. Petersen,Dean A. Shumway,Bradley J. Stish,Elizabeth Yan,Nicholas B. Remmes,Robert W. Mutter,Kimberly S. Corbin
出处
期刊:Advances in radiation oncology [Elsevier BV]
卷期号:6 (1): 100640-100640 被引量:37
标识
DOI:10.1016/j.adro.2020.100640
摘要

Reirradiation poses a distinct therapeutic challenge owing to risks associated with exceeding normal tissue tolerances and possibly more therapeutically resistant disease biology. We report our experience with reirradiation for locoregional recurrent or second primary breast cancer.Between 1999 and 2019, all patients with breast cancer treated with repeat breast/chest wall radiation therapy (RT) at our institution were identified. Adverse events were assessed using the Common Terminology Criteria for Adverse Events v5.0. Fisher exact, Mann-Whitney rank-sum, and unpaired t tests were used for statistical analysis. Freedom from locoregional recurrence and distant metastasis as well as overall survival were calculated using the Kaplan-Meier method.Seventy-two patients underwent reirradiation. Median prior RT dose, reirradiation dose, and cumulative dose were 60 Gy (interquartile range [IQR], 50-60.4 Gy), 45 Gy (IQR, 40-50 Gy), and 103.54 Gy2 (IQR, 95.04-109.62 Gy2), respectively. Median time between RT courses was 73 months (IQR, 29-129 months). Thirty-four patients (47%) had gross residual disease at time of reirradiation. Course intent was described as curative in 44 patients (61%) and palliative in 28 (39%). Fifty-two patients (72%) were treated with photons ± electrons and 20 (28%) with protons. With a median follow-up of 22 months (IQR, 10-43 months), grade 3 adverse events were experienced by 13% of patients (10% acute skin toxicity and 3% late skin necrosis). Time between RT courses and reirradiation fields was significantly associated with the development of grade 3 toxicity at any point. Proton therapy conferred a dosimetric advantage without difference in toxicity. At 2 years, locoregional recurrence-free survival was 74.6% and overall survival was 65.5% among all patients, and 93.1% and 76.8%, respectively, among curative intent patients treated without gross disease. Distant metastasis-free survival was 59.0% among all curative intent patients.Reirradiation for locoregional recurrent breast cancer is feasible with acceptable rates of toxicity. Disease control and survival are promising among curative intent reirradiation patients without gross disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
重要的念文完成签到,获得积分10
1秒前
一骑绝尘发布了新的文献求助10
1秒前
IvanLing发布了新的文献求助10
1秒前
cc发布了新的文献求助10
2秒前
机智谷蕊发布了新的文献求助10
2秒前
李健的小迷弟应助sch采纳,获得10
3秒前
福路路发布了新的文献求助30
3秒前
乖猫要努力应助元谷雪采纳,获得10
4秒前
4秒前
852应助泡菜汤味豆腐采纳,获得10
4秒前
哈哈哈哈完成签到,获得积分10
5秒前
mmc发布了新的文献求助10
5秒前
huangdq6完成签到 ,获得积分10
6秒前
风趣夜云完成签到,获得积分10
7秒前
7秒前
江峰发布了新的文献求助10
7秒前
复杂汲完成签到,获得积分10
7秒前
taybour完成签到,获得积分10
7秒前
8秒前
8秒前
张澳完成签到,获得积分10
8秒前
希望天下0贩的0应助哈喽采纳,获得10
9秒前
机智谷蕊完成签到,获得积分10
9秒前
科目三应助金元宝采纳,获得10
9秒前
Catherine_Song完成签到 ,获得积分10
9秒前
海螺姑娘完成签到,获得积分10
9秒前
SCI发发发完成签到,获得积分20
9秒前
共享精神应助刘亦菲采纳,获得10
10秒前
11秒前
Cici发布了新的文献求助10
11秒前
李健应助重要的天空采纳,获得10
11秒前
欢喜的绝义完成签到 ,获得积分10
11秒前
张澳发布了新的文献求助10
12秒前
12秒前
赵lp.发布了新的文献求助10
12秒前
binol发布了新的文献求助10
12秒前
仁爱绝义完成签到,获得积分20
13秒前
楼亦玉完成签到,获得积分10
13秒前
14秒前
冷傲代亦完成签到,获得积分20
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971277
求助须知:如何正确求助?哪些是违规求助? 3515939
关于积分的说明 11180280
捐赠科研通 3251061
什么是DOI,文献DOI怎么找? 1795664
邀请新用户注册赠送积分活动 875937
科研通“疑难数据库(出版商)”最低求助积分说明 805209